Antiviral chemotherapy for the treatment of hepatitis B virus infections

Gastroenterology

Volumn 118, Issue 2 SUPPL., 2000, Pages

  Torresi, Joseph ^a   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG;

CHEMOTHERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; GENOME; HEPATITIS B; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0033981671     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(00)70008-4     Document Type: Article

References (194)

1. SA Locarnini AL. Cunningham Clinical treatment of viral hepatitis. In Antiviral Chemother DJ eds Jefferies E DeClercq 1995 Wiley, Chichester, England 441 530
2. R. Beasley Hepatitis B virus—the major etiology of hepatocellular carcinoma Cancer 61 1988 1942 1956
3. R Beasley C Lin L Hwang C. Chein Hepatocellular carcinoma and hepatitis B virus Lancet 2 1981 1129 1133
4. D. Ganem Persistent infection of humans with hepatitis B virus: mechanisms and consequences Rev Infect Dis 4 1982 1026 1047
5. H Obata N Hayashi Y. Motoike A prospective study of development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B infection Int J Cancer 25 1980 741
6. M Nassal H. Schaller Hepatitis B virus replication—an update J Viral Hepat 3 1996 217 226
7. J Summers WS. Mason Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate Cell 29 1982 403 415
8. JS Tuttleman C Pourcel J. Summers Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells Cell 47 1986 451 460
9. JE Newbold H Xin M Tencza G Sherman J Dean S Bowden S. Locarnini The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes J Virol 69 1995 3350 3357
10. T Gerelsaikhan J Tavis V. Bruss Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis J Virol 70 1996 4269 4274
11. AR Jilbert TT Wu HM England PM Hall NZ Carp AP O’Connell WS. Mason Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement J Virol 66 1992 1377 1388
12. RJ Lenhoff J. Summers Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus J Virol 68 1994 4565 4571
13. Y Hayashi K. Koike Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA J Virol 63 1989 2936 2940
14. JYN Lau VG Bain NV Naomov HM Smith GJ Alexander R. Williams Effect of interferon-π on hepatitis B viral antigen expression in primary hepatocyte culture Hepatology 14 1991 975 979
15. LG Guidotti T Ishikawa MV Hobbs B Matzke R Schreiber FV. Chisari Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes Immunity 4 1996 25 36
16. S Guilhot ZG Guidotti FV. Chisari Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a post-transcriptional mechanism J Virol 67 1993 7444 7449
17. LB Tsui LG Guidotti T Ishikawa FV. Chisari Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes Proc Natl Acad Sci USA 92 1995 12398 12402
18. T Heise LG Guidotti FV. Chisari La autoantigen specifically recognises a predicted stem-loop in hepatitis B virus RNA J Virol 73 1999 5767 5776
19. C Luscombe S. Locarnini The mechanism of action of antiviral agents in chronic hepatitis B Viral Hepat 2 1996 1 35
20. JM Colacino KA. Staschke The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection Prog Drug Res 50 1998 259 322
21. F Chisari C. Ferrari Hepatitis B virus immunopathogenesis Annu Rev Immunol 13 1995 29 60
22. HF Lohr G Gerken HJ Schlicht KH Meyer zum Buschenfelde B. Fleischer Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B J Infect Dis 68 1993 1133 1139
23. JA Waters S O’Rourke H-J Schlicht HC. Thomas Cytotoxic T cell responses in patients with chronic hepatitis B virus infection undergoing HBe antigen/antibody seroconversion Clin Exp Immunol 102 1995 314 319
24. SL Tsai SN. Huang T cell mechanisms in the immunopathogenesis of viral hepatitis B and C J Gastroenterol Hepatol 12 1997 S227 S235
25. D Kagi F Vignaux B Ledermann K Burki V Depraetere S Nagata H Hengartner P. Golstein Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity Science 265 1994 528 530
26. B Lowin M Hahne C Mattmann J. Tschopp Cytolytic T-cell cytotoxicity is mediated through the perforin and Fas lytic pathways Nature 270 1994 650 652
27. LG Guidotti R Rochford J Chung M Shapiro R Purcell FV. Chisari Viral clearance without destruction of infected cells during acute HBV infection Science 284 1999 825 829
28. G Civitico S. Locarnini The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte culture Virology 203 1994 81 89
29. F Tine A Liberati A Craxi OP Almas L. Pagliaro Interferon treatment in patients with chronic hepatitis B: a meta analysis of the published literature J Hepatol 18 1993 154 161
30. C Niederau T Heintges S Lange G Goldmann CM Niederau L Morh D. Haussinger Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B N Engl J Med 334 1996 1422 1427
31. RP Perillo FG Regenstein MG Peters K DeSchryver-Kecskemeti CJ Bodicky CR Campbell MC. Kuhns Predisolone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis Ann Intern Med 109 1998 95 100
32. DK Wong AM Cheung K O’Rourke CD Naylor AS Detsky J. Heathcote Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 119 1993 312 323
33. M Cohard T Poynard P Mathurin JP. Zarski Prednisolone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis Hepatology 20 1994 1390 1398
34. JH Hoofnagle AM. Di Bisceglie Drug therapy: the treatment of chronic viral hepatitis N Engl J Med 336 1997 347 356
35. AS Lok HT Chung VWS Liu OC. Ma Long-term follow-up of chronic hepatitis B patients treated with interferon alpha Gastroenterology 105 1993 1833 1838
36. S-M Lin I-S Sheen R-N Chein C-M Chu Y-F. Liaw Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 1999 971 975
37. J Korenman B Baker J Waggoner JE Everhart AM Di Bisceglie JH. Hoofnagle Long-term remission of chronic hepatitis B after alpha-interferon therapy Ann Intern Med 114 1991 629 634
38. G Fattovich G McIntyre M Thursz K Colman G Giuliano A Alberti HC Thomas WF. Carman Hepatitis B virus precore/core variation and interferon therapy Hepatology 22 1995 1355 1362
39. G Fattovich G Giustina G Realdi R Corrocher SW. Schalm Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa Hepatology 26 1997 1338 1342
40. JH Hoofnagle AM Di Bisceglie JG Waggoner Y. Park Interferon alpha for patients with clinically apparent cirrhosis due to hepatitis B Gastroenterology 104 1993 1116 1121
41. MR Brunetto F Oliveri M Koehler F. Zahm Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study Lancet 351 1998 1535 1539
42. JH Hoofnagle J. Lau Chronic viral hepatitis—benefits of current therapies N Engl J Med 334 1996 1470 1471
43. RN Chein TC Chen CT Yeh IS. Sheen Efficacy of thymosin alpha 1 in patients with chronic hepatitis B: a randomized, controlled trial Hepatology 27 1998 1383 1387
44. MG Mutchnick K Lindsay E Schiff G Cummingo HD. Appleman Thymosin α1 treatment of chronic hepatitis B: a multicenter placebo-controlled double blind study Gastroenterology 108 1995 A1127 (abstr)
45. MG Mutchnick HD Appleman HT Chung E Aragona TP Guota GD Cummingo JG Waggoner JH Hoofnagle DA. Shafritz Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial Hepatology 14 1991 409 415
46. A Jordan P. Reichard Ribonucleotide reductases Annu Rev Biochem 67 1998 71 98
47. TW. Traut Physiological concentrations of purines and pyrimidines Mol Cell Biochem 140 1994 1 22
48. T Shaw SA. Locarnini Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis Liver 15 1995 169 184
49. T. Shaw The role of blood platelets in nucleoside metabolism: regulation of megakaryocyte development and platelet production Mutat Res 200 1988 67 97
50. ES Arner S. Eriksson Mammalian deoxyribonucleoside kinases Pharmacol Ther 67 1995 155 186
51. J Mercader M Gomez-Angelats B del Santo FJ Casado A Felipe M. Pastor-Anglada Nucleoside uptake in rat liver parenchymal cells Biochem J 317 1996 835 842
52. T Shaw SA. Locarnini Preclinical aspects of lamivudine and famciclovir against hepatitis B virus J Viral Hepat 6 1999 89 106
53. AH Sjoberg L Wang S. Eriksson Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs Mol Pharmacol 53 1998 270 273
54. A Verri G Priori S Spadari L Tondelli F. Focher Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L nucleoside analogues Biochem J 328 1997 317 320
55. L Wang B Munch-Petersen A Herrstrom Sjoberg U Hellman T Bergman H Jornvall S. Eriksson Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates FEBS Lett 443 1999 170 174
56. A Verri F Focher G Priori G Gosselin JL Imbach M Capobianco A Garbesi S. Spadari Lack of enantiospecificity of human 2′-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents Mol Pharmacol 51 1997 132 138
57. H Yan MD. Tsai Nucleoside monophosphate kinases: structure, mechanism, and substrate specificity Adv Enzymol Relat Areas Mol Biol 73 1999 103 134
58. EH. Postel NM23-NDP kinase Int J Biochem Cell Biol 30 1998 1291 1295
59. R Mancini L Marucci A Benedetti AM Jezequel F. Orlandi Immunohistochemical analysis of S-phase cells in normal human and rat liver by PC10 monoclonal antibody Liver 14 1994 57 64
60. SJ Heydrick BR Lardeux GE. Mortimore Uptake and degradation of cytoplasmic RNA by hepatic lysosomes. Quantitative relationship to RNA turnover J Biol Chem 266 1991 8790 8796
61. PB Gahan J. Middleton Hepatocyte euploidization is a typical mammalian physiological specialization Comp Biochem Physiol [A] 71 1982 345 348
62. MG Sturgill GH. Lambert Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function Clin Chem 43 1997 1512 1526
63. SS Wachtel TR. Tiersch Variations in genome mass Comp Biochem Physiol [B] 104 1993 207 213
64. DL Croteau VA. Bohr Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells J Biol Chem 272 1997 25409 25412
65. RD Wood MK. Shivji Which DNA polymerases are used for DNA-repair in eukaryotes? Carcinogenesis 18 1997 605 610
66. K Bouayadi JS Hoffmann P Fons M Tiraby JP Reynes C. Cazaux Overexpression of DNA polymerase beta sensitizes mammalian cells to 2′,3′-deoxycytidine and 3′-azido-3′-deoxythymidine Cancer Res 57 1997 110 116
67. GS Shadel DA. Clayton Mitochondrial DNA maintenance in vertebrates Annu Rev Biochem 66 1997 409 435
68. RC. Scarpulla Nuclear control of respiratory chain expression in mammalian cells J Bioenerg Biomembr 29 1997 109 119
69. KL Veltri M Espiritu G. Singh Distinct genomic copy number in mitochondria of different mammalian organs J Cell Physiol 143 1990 160 164
70. ME King GC Godman DW. King Respiratory enzymes and mitochondrial morphology of HeLa and L cells treated with chloramphenicol and ethidium bromide J Cell Biol 53 1972 127 142
71. MP King G. Attardi Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation Science 246 1989 500 503
72. C Richter M Suter PB. Walter Mitochondrial free radical damage and DNA repair Biofactors 7 1998 207 208
73. J Hayashi M Takemitsu Y Goto I. Nonaka Human mitochondria and mitochondrial genome function as a single dynamic cellular unit J Cell Biol 125 1994 43 50
74. RN Lightowlers PF Chinnery DM Turnbull N. Howell Mammalian mitochondrial genetics: heredity, heteroplasmy and disease Trends Genet 13 1997 450 455
75. SW Graves AA Johnson KA. Johnson Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase Biochemistry 37 1998 6050 6058
76. F Focher G Maga A Bendiscioli M Capobianco F Colonna A Garbesi S. Spadari Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5′-triphosphate Nucleic Acids Res 23 1995 2840 2847
77. AA Krayevsky NB Dyatkina DG Semizarov LS Victorova EA Shirokova F Theil MV Von Janta Lipinski G Gosselin JL. Imbach Reasons and limits of substrate activity of modified L-dNTP in DNA biosynthesis Nucleosides Nucleotides 18 1999 863 864
78. M Davis JE Wilson NA VanDraanen WH Miller GA Freeman SM Daluge FL Boyd AE Aulabaugh GR Painter LR. Boone DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs Antiviral Res 30 1996 133 145
79. JY Feng KS. Anderson Mechanistic studies comparing the incorporation of (+) and (−) isomers of 3TC by HIV-1 reverse transcriptase Biochemistry 38 1999 55 63
80. G Maga M Amacker U Hubscher G Gosselin JL Imbach C Mathe A Faraj JP Sommadossi S. Spadari Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3′-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D- and L-enantiomers of deoxy-and dideoxy-nucleoside triphosphate analogs Nucleic Acids Res 27 1999 972 978
81. S Doong C Tsai R Schinazi D Liotta Y. Cheng Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues Proc Natl Acad Sci USA 88 1991 8495 8499
82. CN Chang S Doong J Zhou J Beach L Jeong C Chu C Tsai Y Cheng D Liotta R. Schinazi Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/−)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication J Biol Chem 267 1992 13938 13942
83. A Severini X Liu J Wilson D. Tyrrell Mechanism of inhibition of duck hepatitis B virus polymerase by (−)-beta-L-2′,3′-dideoxy-3′-thiacytidine Antimicrob Agents Chemother 39 1995 1430 1435
84. J Kruining RA Heijtink SW. Schalm Antiviral agents in hepatitis B virus-transfected cell lines: inhibitory and cytotoxic effect related to time of treatment J Hepatol 22 1995 263 267
85. WE Delaney TG Miller HC. Isom Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (−)- 2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA Antimicrobial Agents Chemother 43 1999 2017 2026
86. GJ Hart DC Orr CR Penn HT Figueiredo NM Gray RE Boehme JM. Cameron Effects of (−)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma Antimicrob Agents Chemother 36 1992 1688 1694
87. C Chang V Skalski J Zhou Y. Cheng Biochemical pharmacology of (+)- and (−)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents J Biol Chem 267 1992 22414 22420 5
88. C Asia Hepatitis Lamivudine Study GroupLai R Chien N Leung T Chang R Guan D Tai K Ng P Wu J Dent J Barber S Stephenson D. Gray A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 1998 61 68
89. J Dienstag R Perrillo E Schiff M Bartholomew C Vicary M. Rubin A preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 333 1995 1657 1661
90. E Jaeckel MP. Manns Experience with lamivudine against hepatitis B virus Intervirology 40 1997 322 336
91. F Nevens J Main P Honkoop DL Tyrell J Barber MT Sulivan J Fevery RA DeMan HC. Thomas Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study Gastroenterology 113 1997 1258 1263
92. J Dienstag ER Schiff TL Wright RP Perillo H-WL Hanh Z Goodman L Crowther LD Condreay M Woessner M Rubin NA. Brown Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
93. J Dienstag ER Schiff M Mitchell DE Casey N Gitlin G Lissoos LD Gelb L Condreay L Crowther M Rubin N. Brown Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy Hepatology 30 1999 1082 1087
94. Y-F Liaw R-N Chien C-T Yeh S-L Tsai C-M. Chu Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 30 1999 567 572
95. P Honkoop RA de Man RA Heijtink SW. Schalm Hepatitis B reactivation after lamivudine (letter) Lancet 346 1995 1156 1157
96. B-C Song DJ Suh HC Lee Y-H Chung YS. Lee Seroconversion after lamivudine treatment is not durable in chronic hepatitis B Hepatology 30 1999 A245 (abstr)
97. H Fontaine F Driss J-L Lagneau H Zylberger C Brechot S Pol C. Necker Hepatitis B virus reactivation after lamivudine discontinuation Hepatology 30 1999 A754 (abstr)
98. RN Chien YF Liaw M. Atkins Pretherapy alanine transaminase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B Hepatology 30 1999 770 774
99. NC Tassopoulos R Volpes G Pastore J Heathcote M Buti RD Goldin S Hawley J Barber L Condreay DF. Gray Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Hepatology 29 1999 889 896
100. VG Bain NM Kneteman MM Ma K Gutfreund JA Shapiro K Fischer G Tipples H Lee LD Jewell DL. Tyrrell Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation Transplantation 62 1996 1456 1462
101. A Marzano W Debernardi-Venon L Condreay M. Rizzetto Efficacy of lamivudine re-treatment in a patient with hepatitis B virus (HBV) recurrence after liver transplantation and HBV-DNA breakthrough during the first treatment Transplantation 65 1998 1499 1500
102. L Grellier D Mutimer M Ahmed D Brown AK Burroughs K Rolles P McMaster P Beranek F Kennedy H Kibbler P McPhillips E Elias G. Dusheiko Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis Lancet 348 1996 1212 1215
103. JI Herrero J Quiroga B Sangro I Sola JI Riezu-Boj F Pardo J. Prieto Effectiveness of lamivudine in the treatment of acute recurrent hepatitis B after liver transplantation Dig Dis Sci 43 1998 1186 1189
104. JR Nery D Weppler M Rodriguez P Ruiz ER Schiff AG. Tzakis Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation Transplantation 65 1998 1615 1621
105. JS Markowitz P Martin AJ Conrad JF Markmann P Seu H Yersiz JA Goss P Schmidt A Pakrasi L Artinian NG Murray DK Imagawa C Holt LI Goldstein R Stribling RW. Busuttil Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin Hepatology 28 1998 585 589
106. P Honkoop RA de Man PE Zondervan SW. Schalm Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine Liver 17 1997 103 106
107. MM Bartholomew RW Jansen LJ Jeffers KR Reddy LC Johnson H Bunzendahl LD Condreay AG Tzakis ER Schiff NA. Brown Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation Lancet 349 1997 20 22
108. R Ling D Mutimer M Ahmed EH Boxall E Elias GM Dusheiko TJ. Harrison Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine Hepatology 24 1996 711 713
109. GA Tipples MM Ma KP Fischer VG Bain NM Kneteman DL. Tyrrell Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo Hepatology 24 1996 714 717
110. RA De Man AI Bartholomeusz HGM Niesters PE Zondervan SA. Locarnini The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response followed by lamivudine resistance resulting in graft loss J Hepatol 29 1998 669 675
111. S Peek I Toshkov H Erb R Schinazi B Korba P Cote J Gerin B. Tennant 3′-thiacytidine (3TC) delays development of hepatocellular carcinoma (HCC) in woodchucks with experimentally induced chronic woodchuck hepatitis virus (WHV) infection. Preliminary results of a lifetime study Hepatology 26 1997 A957 (abstr)
112. Z Goodman AP Dhillon PC Wu F Gray M Atkins C Stevenson J Barber N Brown L Crowther M. Woessner Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B J Hepatol 30 1999 59
113. P Honkoop RE De Man HR Scholte PE Zondervan WO Van Den Berg LHPM Rademakers SW. Schalm Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B Hepatology 26 1997 211 215
114. A Bartholomeusz L Groenen S. Locarnini Clinical experience with famciclovir against hepatitis B virus Intervirology 40 1997 337 342
115. M Boyd S Safrin E. Kern Penciclovir: a review of its spectrum of activity, selectivity, and cross resistance pattern Antiviral Chem Chemother 4 1993 3 11
116. R. Vere Hodge Review: antiviral portrait series number 3. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir Antiviral Chem Chemother 4 1993 67 84
117. K Tsiquaye M Slomka M. Maung Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo J Med Virol 42 1994 306 310
118. T Shaw P Amor G Civitico M Boyd S. Locarnini In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus Antimicrob Agents Chemother 38 1994 719 723
119. D Earnshaw T Bacon S Darlison K Edmonds R Perkins R. Vere Hodge Penciclovir: mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus [HSV 1], HSV-2 and varicella zoster virus Antimicrob Agents Chemother 36 1992 2747 2757
120. BE Korba MR. Boyd Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells Antimicrobial Agents Chemother 40 1996 1282 1284
121. T Shaw S Mok S. Locarnini Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir Hepatology 24 1996 996 1002
122. E Lin C Luscombe Y Wang T Shaw S. Locarnini The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo Antimicrob Agents Chemother 40 1996 413 418
123. S Locarnini E Lin C Luscombe P Edwards D Anderson T. Shaw Penciclovir: a novel nucleoside analogue with potent activity against duck hepatitis B virus in vitro Antiviral Res 26 1995 A242 (abstr)
124. B Lee W Luo S Suzuki M Robins D. Tyrrell In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus Antimicrob Agents Chemother 33 1989 336 339
125. K Tsiquaye D Sutton M Maung MR. Boyd Antiviral activities and pharmacokinetics of penciclovir and famciclovir in pekin ducks chronically infected with duck hepatitis B virus Antiviral Chem Chemother 7 1996 153 159
126. Y Wang S Bowden T Shaw G Civitico Y Chan M Qiao S. Locarnini Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir [9-[2-hydroxy-1-[hydroxymethyl]ethoxymethyl]guanine] Antiviral Chem Chemother 2 1991 107 114
127. TT Wu L Coates CE Aldrich J Summers WS. Mason In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway Virology 175 1990 255 261
128. J Main L Brown C Howells R Calassini M Crossey P Korayiannis P Georgiou G Atkinson HC. Thomas A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection J Viral Hepat 3 1996 211 215
129. C. Trepo Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study Hepatology 24 1996 A188 (abstr)
130. K Benner H Rosen K. Flora Famciclovir treatment of decompensated HBV cirrhosis Hepatology 24 1996 A622 (abstr)
131. T Aye A Bartholomeusz T Shaw S Bowden A Breschkin J McMillan P Angus S. Locarnini Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation J Hepatol 26 1997 1148 1153
132. M Kruger HL Tilman C Trautwein U Bode K Oldhafer H Maschek KH Boker CE Broelach R Pichimayr MP. Manns Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study Liver Transplant Surg 40 1996 413 418
133. K Boker B Ringe M Kruger R Pichlmayr M. Manns Prostaglandin E plus famciclovir—a new concept for the treatment of severe hepatitis B after liver transplantation Transplantation 57 1994 1706 1708
134. GK Lau R Liang PC Wu CK Lee WL Lim WY. Au Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation J Hepatol 28 1998 359 368
135. N Singh T Gayowski CF Wannstedt MM Wagenner IR. Marino Pre-transplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation Transplantation 63 1997 1415 1419
136. R Cirelli K Herne M Mc Crary P Lee SK. Tyring Famciclovir: review of clinical efficacy and safety Antiviral Res 29 1996 141 151
137. L Naesens R Snoeck G Andrei J Balzarini J Neyts E. De Clerq HPMPC [cidofovir], PMEA [adefovir] and related acyclic nucleoside phosphonate analogues: preview of their pharmacology and clinical potential in the treatment of viral infections Antiviral Chem Chemother 8 1997 1 23
138. J Balzarini Z Hao P Herdewijn D Johns E. De Clercq Intracellular metabolism and mechanism of anti-retrovirus action of 9-[2-phosphonylmethoxyethyl]adenine, a potent anti-human immunodeficiency virus compound Proc Natl Acad Sci USA 88 1991 1499 1503
139. T Yokota S Mochizuki K Konno S Mori S Shigeta E. De Clercq Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis Antimicrob Agents Chemother 35 1991 394 397
140. R Heijtink G De Wilde J Kruning L Berk J Balzarini E DeClercq A Holy SW. Schalm Inhibitory effect of 9-[2-phosphonoyl-methoxyethyl]-adenine (PMEA) on human and duck hepatitis B virus infection Antiviral Res 21 1993 141 153
141. R Heijtink J Kruining G de Wilde J Balzarini E de Clercq S. Schalm Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture Antimicrob Agents Chemother 38 1994 2180 2182
142. A Nicoll D Colledge J Toole P Angus R Smallwood S. Locarnini Inhibition of duck hepatitis B virus replication by 9-[2-phosphonylmethoxyethyl]adenine, an acyclic phosphonate nucleoside analogue Antimicrob Agents Chemother 42 1998 3130 3135
143. SG Deeks A Collier J Lalezra A Pavia D Rodrigue WL Drew J Toole HS Jaffe PD Lamy W Li JM Cherrington N Hellmann J. Kahn The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomised, double-blind, placebo-controlled trial J Infect Dis 176 1997 1517 1523
144. KC Cundy P Barditch-Crovo RE Walker AC Collier D Ebling J Toole HS. Jaffe Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients Antimicrob Agents Chemother 39 1995 2401 2405
145. R Gilson K Chopra I Murray-Lyon A Newell M Nelson R Tedder J Toole HS Jaffe N Hellmann IVD. Weller A placebo controlled phase I/II study of adefovir dipivoxil [Bis-POM PMEA] in patients with chronic hepatitis B infection Hepatology 24 1996 A620 (abstr)
146. L Jeffers E Heathcote T Wright R Carithers A di Bisceglie R Perille V. Rustgi A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection Antiviral Res 37 1998 A197 (abstr)
147. X Xiong C Flores H Yang JJ Toole CS. Gibbs Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro Hepatology 28 1999 1669 1673
148. L Fu S-H Liu Y-C. Cheng Sensitivity of L-(-)2′,3′-dideoxythiacytidine resistant hepatitis B virus to other nucleoside analogues Biochem Pharmacol 57 1999 1351 1359
149. SK Ono-Nita N Kato Y Shiratori K-H Lan H Yohida FJ Carrilho M. Omata Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors J Clin Invest 103 1999 1635 1640
150. R Perillo E Schiff A Magil A. Murray In vivo demonstration of sensitivity of YMDD variants to adefovir Hepatology 30 1999 122 (abstr)
151. KC. Cundy Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir Clin Pharmacokinet 36 1999 127 143
152. C Luscombe J Pedersen S Bowden S. Locarnini Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy Liver 14 1994 182 192
153. P Angus M Richards S Bowden J Ireton R Sinclair B Jones S. Locarnini Combination chemotherapy controls severe post-liver transplant recurrence of hepatitis B virus infection J Gastroenterol Hepatol 8 1993 353 357
154. RG Gish JY Lau L Brooks JW Fang SL Steady JC Imperial R Garcia-Kennedy CO Esquivel EB. Keeffe Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients Hepatology 23 1996 1 7
155. SJ Hadziyannis EK Manesis A. Papakonstantinou Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study Hepatology 31 1991 210 214
156. PL Shields R Ling T Harrison E Boxall E Elias DJ. Mutimer Management and outcome of lamivudine(LAM)-resistant hepatitis B virus (HBV) infection after liver transplantation Hepatology 26 1997 A260 (abstr)
157. A Field A Tuomari B McGeever-Rubin B Terry K Mazina M Haffey M Hagen J Clark A Braitman W Slusarchyk MG Young R. Zahler (+)-[1 alpha,2 beta,3alpha]-9-[2,3-bis[hydroxymethyl]-cyclobutyl]guanine[(+−)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses Antiviral Res 13 1990 41 52
158. L Hung A Brumbaugh G Bhatia P Marion P Hung D Norbeck J Plattner W. Robinson Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture J Med Virol 35 1991 180 186
159. J Bloomer R Chan M Sherman P Ingraham D. DeHertogh A preliminary study of lobucavir for chronic hepatitis B Hepatology 26 1996 A1199 (abstr)
160. G Yamanaka A Tuomari M Hagen B McGeever-Rubin B Terry M Haffey G Bisacchi A. Field Selective activity and cellular pharmacology of [1R-1 alpha,2 beta,3 alpha]-9-[2,3-bis[hydroxymethyl]cyclobutyl]guanine in herpesvirus-infected cells Mol Pharmacol 40 1991 446 453
161. B Terry C Cianci M. Hagen Inhibition of herpes simplex virus type 1 DNA polymerase by [1R[1 alpha,2 beta,3 alpha]]-9-[2,3-bis[hydroxymethyl]cyclobutyl] guanine Mol Pharmacol 40 1991 591 596
162. N Ikeda S Kaneko A Shimoda Y Inagaki M Unoura M Okada Y Yonekawa K Takahashi K. Kobayashi Efficiency of oxetanocin-G, a novel nucleoside against the woodchuck hepatitis virus J Antimicrob Chemother 33 1995 83 89
163. M Seifer RK Hamatake RJ Colonno DN. Standring In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir Antimicrob Agents Chemother 28 1998 3200 3208
164. EV Genovesi L Lamb I Medina D Taylor M Seifer S Innaimo RJ Colonno DN Standring JM. Clark Efficacy of the carbocyclic 2′ deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection Antimicrob Agents Chemother 42 1998 3209 3217
165. S Innaimo M Seifer G Bisacchi D Standring R Zahler R. Colonno Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus Antimicrob Agents Chemother 41 1997 1444 1448
166. G Yamanaka T Wilson S Innaimo GS Bisacchi P Egli JK Rinehart R Zahler RJ. Colonno Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus Antimicrob Agents Chemother 43 1999 190 193
167. PA Furman M Davis DC Liotta M Paff LW Frick DJ Nelson RE Dornsife JA Wurster LJ Wilson JA. Fyfe The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (−) and (+) enantiomers of cis -5-fluoro-1-(2-[hydroxymethyl]-1,3-oxythiolan-5-yl)-cytosine (FTC) Antimicrob Agents Chemother 36 1992 2686 2692
168. L Cui RF Schinazi G Gosselin JL Imbach CK Chu RF Rando GR Revankar JP. Sommadossi Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity Biochem Pharmacol 52 1996 1577 1584
169. MT Paff DR Averett KL Prus WH Miller DJ. Nelson Intracellular metabolism of (−) and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells Antimicrob Agents Chemother 38 1994 1230 1238
170. SK Ladner TJ Miller MJ Otto RW. King The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues Antiviral Chem Chemother 9 1998 65 72
171. KP Fischer DL. Tyrrell Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine (−)-beta-L-2′, 3′-dideoxy-3′-thiacytidine) in vitro Antimicrobial Agents Chemother 40 1996 1957 1960
172. LW Frick L St John LC Taylor GR Painter PA Furman DC Liotta ES Furfine DJ. Nelson Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (−)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus Antimicrob Agents Chemother 37 1993 2285 2292
173. HL Tillmann C Trautwein T Bock KWH Boker E Jackel M Glowienka K Oldhafer J Bruns LD Condreay HR Raab MP. Manns Mutational analysis of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation Hepatology 30 1999 244 256
174. H Tillmann C Trautwein M Kruger K Boker H Schlitt L Condreay M Deslauriars I Bruns R Pichlmayr M. Manns Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation J Hepatol 26 1997 153
175. O Poch I Sauvaget M Delarue N. Tordo Identification of four conserved motifs among the RNA-dependent polymerase encoding elements EMBO J 8 1989 3867 3874
176. A Jacobo-Molina J Ding AD Clark X Lu C Tantillo RL Williams G Kamer AL Ferria P. Clark Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA Proc Natl Acad Sci USA 90 1993 6320 6324
177. A Bartholomeusz RF Schinazi SA. Locarnini Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease Viral Hepat Rev 3 1998 167 187
178. MI Lamivudine Clinical Investigation GroupAllen M Deslauriers CW Andrews GA Tipples KA Walters DL Tyrrell N Brown LD. Condreay Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine Hepatology 27 1998 1670 1677
179. K Chayama Y Suzuki M Kobayashi M Kobayashi A Tsubota M Hashimoto Y Miyano H Koike M Kobayashi I Koida Y Arase S Saitoh N Murashima K Ikeda H. Kumada Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy Hepatology 27 1998 1711 1717
180. EM Yoshida MM Ma JE Davis KP Fischer NM Kneteman SR Erb DL Tyrrell VG. Bain Post-liver transplant allograft reinfection with a lamivudine resistant strain of hepatitis B virus: long-term follow-up Can J Gastroenterol 12 1998 125 129
181. P Honkoop HG Niesters RA de Man AD Osterhaus SW. Schalm Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns J Hepatol 26 1997 1393 1395
182. M Melegari PP Scaglioni J. Wands Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective Hepatology 27 1998 628 633
183. C Pichoud B Seigners Z Wang C Trepo F. Zoulim Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance Hepatology 29 1998 230 237
184. SA Locarnini C. Birch Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients J Hepatol 30 1999 536 550
185. MA Nowak S Bonhoeffer A Hill R Boehme HC Thomas H. McDade Viral dynamics in hepatitis B virus infection Proc Natl Acad Sci USA 93 1996 4398 4402
186. S Zeuzem RA de Man P Honkoop WK Roth SW Schalm JM. Schmidt Dynamics of hepatitis B infection in vivo J Hepatol 27 1997 431 436
187. M Tsiang JF Rooney JJ Toole CS. Gibbs Biphase clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy Hepatology 29 1999 1863 1869
188. D Colledge S Locarnini T. Shaw Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro Hepatology 26 1997 216 225
189. GKK Lau M Tsiang J Hou C. Gibbs Clearance kinetics of HBV infection in Chinese patients: lamivudine versus lamivudine plus famciclovir Hepatology 30 1999 A732 (abstr)
190. L Corey KK. Holmes Therapy for human immunodeficiency virus infection—what have we learned? N Engl J Med 335 1996 1142 1144
191. MD De Jong CA Boucher DA Cooper GJ Galasso B Gazzard JM Lange JS Montaner DD. Richman Summary of the II International Consensus Symposium on combined antiviral therapy and implications for future therapies Antiviral Res 35 1997 65 82
192. AS. Lok Treatment of chronic hepatitis B J Viral Hepat 1 1994 105 124
193. S. Hadziyannis Hepatitis Be antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment Viral Hepat Rev 1 1995 7 36
194. RW Jansen LC Johnson DR. Averett High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay Antimic Agents Chemother 37 1993 441 447